Skip to content
Peptigraph home

Cagrilintide Phase 1 trial (NCT05564104)

A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy Volunteers

Registry record checked

At a glance

Phase
Phase 1
Status
Completed
Enrolment
32
actual
Start
5 Apr 2023 (actual)
Primary completion
6 Sep 2024 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT05564104 study arms
ArmTypeInterventionsDescription
Part A: Participants with normal hepatic functionExperimentalDrug: CagrilintideParticipants with normal hepatic function will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
Part A: Participants with mild hepatic impairmentExperimentalDrug: CagrilintideParticipants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
Part A: Participants with moderate hepatic impairmentExperimentalDrug: CagrilintideParticipants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
Part A: Participants with severe hepatic impairmentExperimentalDrug: CagrilintideParticipants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
Part B: Sequence 1ExperimentalDrug: CagrilintideHealthy participants will receive a single dose of cagrilintide Dose 1 intravenously (i.v) at the first dosing visit (Day 1), followed by a single dose of cagrilintide Dose 2 s.c. at the second dosing visit (Day 53).
Part B: Sequence 2ExperimentalDrug: CagrilintideHealthy participants will receive a single dose of cagrilintide Dose 2 s.c. at the first dosing visit (Day 1), followed by a single dose of cagrilintide Dose 1 i.v at the second dosing visit (Day 53).
Endpoints

Primary endpoint

NCT05564104 primary outcomes
MeasureTime frame
Part A: AUC 0-infinity (∞), single dose (SD), cagri: The area under the cagrilintide plasma concentration-time curve fromtime 0 to infinity after a single doseFrom 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 840 hours (post dose)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05564104 secondary outcomes
MeasureTime frame
Part A: Cmax,SD,cagri: Maximum observed plasma cagrilintide concentration after a single doseFrom 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96 to 120 hours (post dose)
Part A: Tmax,SD,cagri: Time to maximum observed plasma cagrilintide concentration after a single doseFrom 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96 to 120 hours (post dose)
Part A: T½ SD,cagri:Terminal half-life for cagrilintide after a single doseFrom 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 840 hours (post dose)
Part A: CL/F SD,cagri:Apparent clearance of cagrilintide after a single doseFrom 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 840 hours (post dose)
Part B: AUC0-∞,SD,cagri: The area under the cagrilintide plasma concentration-time curve from time 0 to infinity after a single doseFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose)
Part B: AUC0-last,SD,cagri: The area under the cagrilintide plasma concentration-time curve from time 0 to last quantifiable observationFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose)
Part B: Cmax,SD,cagri: Maximum observed plasma cagrilintide concentration after a single doseFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96 to 120 hours (post dose)
Part B: tmax,SD,cagri: Time to maximum observed plasma cagrilintide concentration after a single doseFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96 to 120 hours (post dose)
Part B: t½ SD,cagri: Terminal half-life for cagrilintide after a single doseFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose)
Part B: CL/F SD,cagri: Apparent clearance of cagrilintide after a single s.c. doseFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose)
Part B: CL SD,cagri: Apparent clearance of cagrilintide after a single i.v. doseFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose)
Part B: V z/F,cagri: Volume of distribution of cagrilintide after a single s.c. doseFrom 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Results

Results

No results posted on ClinicalTrials.gov as of 11 Oct 2026.

Hepatic impairment and a single cagrilintide dose

The registry title describes a single-dose cagrilintide study in people with reduced liver function and in healthy volunteers.[1]

Against normal liver function, mean AUC ratios were 0.99, 1.01 and 1.11 for mild, moderate and severe hepatic impairment.[2]

In both impairment studies, no serious treatment-emergent adverse events, withdrawals due to such events, or deaths were reported.[2]

The authors saw no rise in adverse events as renal or hepatic impairment increased.[2]

Sources

  1. 1A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy VolunteersClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 11 Oct 2026
  2. 2Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026

Found an error? Report a correction.